In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologie and transcriptional profiling

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 7, 2006, Pages 2384-2394

  Andes, D ^a,b   Lepak, A ^a,b   Nett, J ^a,b   Lincoln, L ^a,b   Marchillo, K ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CANDIDA ALBICANS; CELL POPULATION; CONTROLLED STUDY; DRUG DOSE REGIMEN; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; FUNGAL PROTEINS; GENE EXPRESSION PROFILING; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; SPECIFIC PATHOGEN-FREE ORGANISMS; TRANSCRIPTION, GENETIC;

EID: 33745614658     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01305-05     Document Type: Article

References (49)

1. Andes, D., A. Forrest, A. Lepak, J. Nett, K. Marchillo, and L. Lincoln. 2006. Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans. Antimicrob. Agents Chem. 50:2374-2383.
2. Andes, D., A. Lepak, A. Pitula, K. Marchillo, and J. Clark. 2005. A simple approach for estimating gene expression of Candida albicans directly from a systemic infection site. J. Infect. Dis. 192:893-900.
3. Andes, D., and M. Van Ogtrop. 1999. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis model. Antimicrob. Agents Chemother. 43:2116-2120.
4. Andes, D. 2003. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob. Agents Chemother. 47:1179-1186.
5. Baddley, J. W., and S. A. Moser. 2004. Emerging fungal resistance. Clin. Lab. Med. 24:721-735.
6. Barker, K. S., S. Crisp, R. E. Wiederhold, R. E. Lewis, B. Bareither, J. Eckstein, R. Barbuch, M. Bard, and P. D. Rogers. 2004. Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans. J. Antimicrob. Chemother. 54:376-385.
7. Blaser, J., B. B. Stone, M. C. Groner, and S. H. Zinner. 1987. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother. 31:1054-1060.
8. Bonhoeffer, S., M. Lipsitch, and B. R. Levin. 1997. Evaluating treatment protocols to prevent antibiotic resistance. Proc. Natl. Acad. Sci. USA 94:12106-12111.
9. Bouma, J. E., and R. E. Lenski. 1988. Evolution of a bacteria/plasmid association. Nature 335:351-352.
10. Bustin, S. A. 2000. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J. Mol. Endocrinol. 25:169-193.
11. Cowen, L. E., A. Nantel, M. S. Whiteway, D. Y. Thomas, D. C. Tessier, L. M. Kohn, and J. B. Anderson. 2002. Population genomics of drug resistance in Candida albicans. Proc. Natl. Acad. Sci. USA 99:9284-9289.
12. Cowen, L. E., L. M. Kohn, and J. B. Anderson. 2001. Divergence of fitness and evolution of drug resistance in experimental populations of Candida albicans. J. Bacteriol. 183:2971-2978.
13. Drusano, G. L., D. E. Johnson, M. Rosen, and H. C. Standiford. 1993. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37:483-490.
14. Ehrenhofer-Murray, A. E., M. U. Keller Seitz, and C. Sengstag. 1998. The Sge1 protein of Saccharomyces cerevisiae is a membrane-associated multidrug transporter. Yeast 14:49-65.
15. Fan-Harvard, P., D. Capano, S. M. Smith, A. Mangia, and R. H. K. Eng. 1991. Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy. Antimicrob. Agents Chemother. 35:2302-2305.
16. Firsov, A. A., S. N. Vostrov, I. Y. Lubenko, K. Drlica, Y. A. Portnoy, and S. H. Zinner. 2003. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1604-1613.
17. Fish, D. N., S. C. Piscitelli, and L. H. Danziger. 1995. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 15:279-291.
18. Gabriel, I., J. Olchowy, A. Stanislawska-Sachadyn, T. Mio, J. Kur, and S. Milewski. 2004. Phosphorylation of glucosamine-6-phosphate synthase is important but not essential for germination and mycelial growth of Candida albicans. FEMS Microbiol. Lett. 235:73-80.
19. Gerber, A. U., A. P. Vastola, J. Brandel, and W. A. Craig. 1982. Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model. J. Infect. Dis. 146:691-697.
20. Grilley, M. M., S. D. Stock, R. C. Dickson, R. L. Lester, and J. Y. Takemoto. 1998. Syringomycin action gene SYR2 is essential for sphingolipid 4-hydroxylation in Saccharomyces cerevisiae. J. Biol. Chem. 273:11062-11068.
21. Jumbe, N., A. Louie, R. Leary, W. Liu, M. R. Deziel, V. H. Tam, R. Bachhawat, C. Freeman, J. B. Kahn, K. Bush, M. N. Dudley, M. H. Miller, and G. L. Drusano. 2003. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Investig. 112:275-285.
22. Karababa, M., A. T. Coste, B. Rognon, J. Bille, and D. Sanglard. 2004. Comparison of gene expression profiles of Candida albicans azole-resistant clinical isolates and laboratory strains exposed to drugs inducing multidrug transporters. Antimicrob. Agents Chemother. 48:3064-3079.
23. Lamb, D. C., D. E. Kelly, W. H. Schunck, A. Z. Shyadehi, M. Akhtar, D. J. Lowe, B. C. Baldwin, and S. L. Kelly. 1997. The mutation T315A in Candida albicans sterol 14 alpha-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. J. Biol. Chem. 272:5682-5688.
24. Levy, S. B., and B. Marshall. 2004. Antibacterial resistance worldwide: causes, challenges and responses. Nat. Mede. 10(Suppl. 12):S122-S129.
25. Lipsitch, M., and B. R. Levin. 1997. The population dynamics of antimicrobial chemotherapy. Antimicrob. Agents Chemother. 41:363-373.
26. Lipsitch, M., C. T. Bergstrom, and B. R. Levin. 2000. The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. Proc. Natl. Acad. Sci. USA 97:1938-1943.
27. Livak, K. J., S. J. Flood, J. Marmaro, W. Giusti, and K. Deetz. 1995. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl. 4:357-362.
28. -DΔCT method. Methods 25:402-408.
29. Losberger, C., and J. E. Ernst. 1989. Sequence of Candida albicans gene encoding actin. Nucleic Acids Res. 17:9488.
30. Martinez, J. L., and F. Baquero. 2002. Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance. Clin. Microbiol. Rev. 15:647-679.
31. Mio, T., T. Yamada-Okabe, T. Yabe, T. Nakajima, M. Arisawa, and H. Yamada-Okabe. 1997. Isolation of the Candida albicans homologs of Saccharomyces cerevisiae KRE6 and SKN1: expression and physiological function. J. Bacteriol. 179:2363-2372.
32. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
33. Patterson, T. F., S. G. Revankar, W. R. Kirkpatrick, O. Dib, A. W. Fothergill, S. W. Redding, D. A. Sutton, and M. G. Rinaldi. 1996. A simple method for detecting fluconazole-resistant yeasts with chromogenic agar. J. Clin. Microbiol. 34:1794-1797.
34. Perea, S., and T. F. Patterson. 2002. Antifungal resistance in pathogenic fungi. Clin. Infect. Dis. 35:1073-1080.
35. Prasad, R., W. P. De, A. Goffeau, and E. Balzi. 1995. Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Curr. Genet. 27:320-329.
36. Pujol, C., S. Joly, S. R. Lockhart, S. Noel, M. Tibayrenc, and D. R. Soll. 1997. Parity among the randomly amplified polymorphic DNA method, enzyme electrophoresis, and Southern blot hybridization and the repetitive DNA probe Ca3 for fingerprinting Candida albicans. J. Clin. Microbiol. 35:2348-2358.
37. Rogers, P. D., and S. K. Barker. 2002. Evaluation of differential gene expression in fluconazole-susceptible and -resistant isolates of Candida albicans by cDNA microarray analysis. Antimicrob. Agents Chemother. 46:3412-3417.
38. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
39. Sanglard, D., R. Ischer, M. Monod, and J. Bille. 1997. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter. Microbiology 143:405-416.
40. Sanglard, D., F. Ischer, L. Koymans, and J. Bille. 1998. Amino acid substitutions in the cytochrome P-450 lanosterol 14 alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother. 42:241-253.
41. Schmitt, M. E., T. A. Brown, and B. L. Trumpower. 1990. A rapid and simple method for preparation of RNA from Saccharomyces cerevisiae. Nucleic Acids Res. 18:3091-3092.
42. Schrag, S. J., V. Perrot, and B. R. Levin. 1997. Adaptation to the fitness cost of antibiotic resistance in Escherichia coli Proc. R. Soc. Long B 264:1287-1291.
43. Selkon, J. B., S. Devadatta, K. G. Kulkarni, D. A. Mitchison, A. S. L. Narayana, C. Narayanan Nair, and K. Ramachandran. 1964. The emergence of isoniazid-resistant cultures in patients with pulmonary tuberculosis during treatment with isoniazid alone or isoniazid plus PAS. Bull. W. H. O. 31:273-294.
44. Sheehan, D. J., C. A. Hitchcock, and C. M. Sibley. 1999. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 12:40-79.
45. Soustre, I., Y. Letourneux, and F. Karst. 1996. Characterization of the Saccharomyces cerevisiae RTA1gene involved in 7-aminocholesterol resistance. Curr. Genet. 30:121-125.
46. Umebayashi, K., and A. Nakano. 2003. Ergosterol is required for targeting of tryptophan permease to the yeast plasma membrane. J. Cell Biol. 161:1117-1131.
47. White, T. C. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41:1482-1487.
48. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
49. White, T. C., M. A. Pfaller, R. G. Rinaldi, J. Smith, and S. W. Redding. 1997. Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis. 3(Suppl. 1):102-109.